Thursday January 24, 2019

Project ReAnima: A Breakthrough in the field of Neuroscience

The project is now a joint venture between the Philadelphia-based biotech company Bioquark Inc, Revita Life Science and Anupam Hospital

3
//
Representational Image. Brain scan. Image source: www.macleans.ca
  • Dr. Bansal hopes to expand the window of when brain death is determined from the current standard of 6 hours
  • He will recruit people who are declared brain dead and have already started the trial 
  • He expects his first subject to arrive as early as this week with chances of him being a victim of a road accident

Flanked by a restaurant-cum-bar on one side and a gym on the other, Anupam Hospital is like any other small town private nursing home in India but for one minor detail: Project ReAnima, the world’s first clinical trial on the revival of brain dead patients.

A medical marvel if you may call it, but Dr. Himanshu Bansal, an orthopaedician and an expert on ‘central nervous system’, in a small three-storey hospital in Rudrapur has conducted world’s first ever trial to revive brain dead patients using stem cell therapy. The Anupam hospital in Rudrapur which is a small town in Uttarakhand , a state known for its Himalayan Beauty, is now clearing up its top floor to accommodate subjects, which in this case are patients that are declared dead by any hospital in the area.

Image Source:http://drhbf.org/about_dr_bansal.php
Dr. Himanshu Bansal. Image Source: drhbf.org

Don’t mistake this as an attempt to revive patients back to life or reverse the state of brain death- Dr. Bansal corroborates the above statement by adding that he hopes to expand the window of when brain death is determined from the current standard of 6 hours. With ethical approvals in his hand, he says he expects his first subject to arrive as early as this week with chances of him being a victim of a road accident.

Legal Implications

Being the principal investigator of the ‘groundbreaking’ project, and after being proved that this cutting-edge clinical trial project works, Government authorities had given ethical approvals to recruit 20 clinically dead patients. With no laws established for the ‘living dead’ or brain dead patients in India, there were no special permissions or approvals to look into for Dr. Bansal. Any case that requires clinical trials usually needs approvals from Drug Controller General of India before heading on to Institutional Review Board (IRB) for any further procedures.

Follow NewsGram on Twitter: @NewsGram1

Contradictory to the above statement, since the recruits were assumedly dead the permissions from the DCG weren’t required and all the permissions that were needed were simply granted by the IRB. An interesting point to note, Institutional Review Board, in this case, consisted of nothing more than a bunch of local doctors from private hospitals, some even retired, reported The Hindu.

Clarifying the above details, Dr. Bansal added saying “The rules apply only on living patients. We will recruit people who are declared brain dead. We have already registered the trial at CTRI, which is the only requirement since there is a grey area legally when it comes to experimenting on brain dead patients.”

The birth of the ‘groundbreaking’ project

Neuroscience. Imagesource:sputniknews.com
Neuroscience. Imagesource:sputniknews.com

A project that is now a joint venture between the Philadelphia-based biotech company Bioquark Inc, Revita Life Science (of which Dr. Bansal is the owner) and Anupam Hospital started in 2009.

Dr. Bansal witnessed success with two patients, one of whom was a world-renowned athlete. By inducing a certain degree of sensation in comatose patients and without cutting them open, the effects of stem cell therapy were studied by him; these are called “anecdotal studies”.

Follow NewsGram on Twitter: @NewsGram1

Currently, the first phase of the trials is about to start soon, in which for six weeks after the clinically dead patient is got into the facility; the effects will be studied on him using Median Nerve Stimulation and laser therapy. The technical name of the trial is given as ‘First In Human Neuro-Regeneration & Neuro-Reanimation’. BioQuark will provide one-third of the funding for this project.

When asked about the ethical and religious implications of this study on the families Dr. Bansal informed, “Most families will be grateful that their loved ones still have a chance.”

ALSO READ: 

  • Aparna Gupta

    This is really an achievement in field of neuroscience. Hope this will prove successful and help the patients.

  • AJ Krish

    This project will give hope to the families of the victims. If this project succeeds, it will surely revolutionize science and further research will be done to exploit its other uses.

  • Vrushali Mahajan

    If we could revive brain dead patients, it could be one great invention

SHARE
  • Aparna Gupta

    This is really an achievement in field of neuroscience. Hope this will prove successful and help the patients.

  • AJ Krish

    This project will give hope to the families of the victims. If this project succeeds, it will surely revolutionize science and further research will be done to exploit its other uses.

  • Vrushali Mahajan

    If we could revive brain dead patients, it could be one great invention

Next Story

New Sleeping Pill Can Help Patients Wake up in Response to Threat

However, more studies on humans are needed to confirm DORA safety and efficacy, they noted

0
Pills (representational Image), Pixabay

Japanese scientists have shown that a new class of sleeping pill that preserves the ability to wake in response to a threat, unlike the commonly prescribed drugs that muffles a sleeping brain’s “intruder alert”.

Even during sleep the brain continuously processes sensory information, waking us if it detects a threat. But the most widely prescribed class of sleeping pills, known as benzodiazepines, makes us less likely to rouse in response to sensory input.

The findings showed that millions prescribed on these sleeping pills would sleep through a fire alarm as someone vacuuming next to their bed.

 However, the new class of drugs called dual orexin receptor antagonists (DORAs) more selectively targeted the brain’s sleep or wake pathways, which gives them safety advantages over benzodiazepines, said researchers from the Kagoshima University.

These include a reduced “hangover effect”, with DORAs less likely to affect driving ability the day after use.

“Benzodiazepines stimulate the widespread brain receptor GABA-A, which makes us sleepy but also suppresses off-target brain areas – including the ‘gatekeeper’ that decides which sensory inputs to process,” explained author Tomoyuki Kuwaki, Professor at the varsity.

Contraception, Men
New sleeping pill can help patients wake up in response to threat.

In the study, published in Frontiers in Behavioral Neuroscience journal, mice that were given the new experimental hypnotic drug DORA-22 wake as quickly when threatened as drug-free sleepers — and then fall back asleep as quickly as ones given standard sleeping pills, once the threat is gone.

While DORA-22 allows mice to wake to a threat, it still helps them sleep.

Thus, the selectivity of DORAs could make them a safer alternative during sleep as well — by allowing the brain’s sensory gatekeeper to stay vigilant to threats, the researchers said.

Also Read- Here’s What Causes Cancer in Children

However, more studies on humans are needed to confirm DORA safety and efficacy, they noted.

“Although it remains to be seen whether DORAs have the same properties when used in humans, our study provides important and promising insight into the safety of these hypnotics,” Kuwaki said. (IANS)